Celator Pharma Reaches 50% Enrollment For CPX-351 Phase 3 Trial - Quick Facts

(RTTNews) - Celator Pharmaceuticals, Inc. (CPXX) said its Phase 3 study comparing CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen, commonly known as 7+3, as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia has reached 50% of the study's planned enrollment of 300 patients.

The Phase 3 trial is being conducted in partnership with The Leukemia & Lymphoma Society or LLS via. its Therapy Acceleration Program or TAP, that has supported the development of CPX-351 beginning in Phase 2.

Patient enrollment is likely to complete in the fourth quarter of 2014. Initial study data, on secondary endpoints such as remission rate and selected safety data, could be available in the second quarter of 2015. The primary endpoint, overall survival, is projected to be available in the first quarter 2016.